Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 22, 2018

Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome (P1.323)

Patricia Cogram, Robert J. Deacon, Melanie J. von Schimmelmann, Matthew J. During, Brett S. Abrahams
First published April 9, 2018,
Patricia Cogram
1GenDDI Ltd London United Kingdom
2Biomedicine Division, Centre for Systems Biotechnology, Fraunhofer Research Foundation London United Kingdom
3Laboratory of Molecular Neuropsychiatry, Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, National Scientific and Technical Research Council London United Kingdom
4Institute of Ecology and Biodiversity (IEB), Faculty of Science, University of Chile London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Deacon
1GenDDI Ltd London United Kingdom
2Biomedicine Division, Centre for Systems Biotechnology, Fraunhofer Research Foundation London United Kingdom
3Laboratory of Molecular Neuropsychiatry, Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, National Scientific and Technical Research Council London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie J. von Schimmelmann
5Ovid Therapeutics New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. During
5Ovid Therapeutics New York NY United States
6Departments of Neurological Surgery and Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett S. Abrahams
5Ovid Therapeutics New York NY United States
7Departments of Genetics and Neuroscience, Albert Einstein College of Medicine New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome (P1.323)
Patricia Cogram, Robert J. Deacon, Melanie J. von Schimmelmann, Matthew J. During, Brett S. Abrahams
Neurology Apr 2018, 90 (15 Supplement) P1.323;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Fragile X syndrome (FXS), is the most common form of inherited intellectual disability, is characterized by autism-like features that include anxiety, irritability, aggression, hyperactivity, and abnormal restricted and repetitive behaviors.

Background: FXS is caused by mutations that disrupt expression of the FMR1 gene that codes for FMRP, a multifunctional RNA binding protein. Published studies in FXS mouse models point to deficits in extrasynaptic GABAA mediated tonic inhibition.

Design/Methods: Described here are the results of efforts aimed at characterizing the effects of Gaboxadol (aka THIP and OV101), a brain penetrant small molecule specific for delta subunit containing extrasynaptic GABAA receptors (dSEGAs), on behavioral endpoints that are abnormal in Fmr1−/y mice and readily translatable to clinical evaluation in patients.

Results: Acute administration of 0.5 mg/kg Gaboxadol (GBX) to Fmr1 KO2 mice fully normalized behavioral abnormalities relevant to hyperactivity (distance in open field; p<0.0001 for WT-Veh vs. Mut-Veh and p>0.05 for WT-Veh vs. Mut-GBX), anxiety (center distance in open field, number light dark transitions, entries in successive alley test; p<0.0001 for WT-Veh vs. Mut-Veh and p>0.05 for WT-Veh vs. Mut-GBX for all tests), irritability/aggression (number of tail rattles, number of bites, latency to attack; p<0.0001 for WT-Veh vs. Mut-Veh and p>0.05 for WT-Veh vs. Mut-GBX for all tests), and restricted and repetitive behaviors (counterclockwise revolutions, time grooming, stereotypy count; p<0.0001 for WT-Veh vs. Mut-Veh and p>0.05 for WT-Veh vs. Mut-GBX for all tests).

Conclusions: Results support clinical evaluation of OV101, the only clinically characterized dSEGA described, in FXS.

Disclosure: Dr. Cogram has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ovid Pharmaceutical, FRAXA Research Foundation, AMO Pharmaceutical and Neuren Pharmaceutical. Dr. Cogram has received personal compensation in an editorial capacity for Frontiers Ageing Neuroscience. Dr. Deacon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ovid Therapeutics and AMO Pharmaceuticals. Dr. von Schimmelmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ovid Therapeutics. Dr. During has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ovid Therapeutics. Dr. During has received compensation for serving on the Board of Directors of Ovid Therapeutics. Dr. During holds stock and/or stock options in Ovid Therapeutics, which sponsored research in which Dr. During was involved as an investigator. Dr. During holds stock and/or stock options in Ovid Therapeutics. Dr. Abrahams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ovid Therapeutics. Dr. Abrahams has received royalty, license fees, or contractual rights payments from UCLA.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise